Chemical and pharmacological characterization of triptans

1. Klára G, Zsuzsanna F. A farmakológia alapjai. Medicina; 2011 p. 216-225.Search in Google Scholar

2. Beale JM, Block JH, editors. Wilson and Gisvold’s Textbook of organic medicinal and pharmaceutical chemistry. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011 p 811-818.Search in Google Scholar

3. Shepherd AJ, Joly-Mascheroni RM. Visual motion processing in migraine: enhanced motion after-effects are related to display contrast, visual symptoms, visual triggers and attack frequency. Cephalalgia. 2017 Apr;37(4):315-26.10.1177/033310241664051927106927Search in Google Scholar

4. Tabet P, Saliba I. Meniere’s disease and vestibular migraine: updates and review of the literature. J Clin Med Res. 2017 Sep;9(9):733–744.10.14740/jocmr3126w554447728811849Search in Google Scholar

5. Shah DR, Dilwali S, Friedman DI. Current Aura Without Headache. Curr Pain Headache Rep. 2018 Nov 1;22(11):77.10.1007/s11916-018-0725-130225597Search in Google Scholar

6. Vgontzas A, Burch R. Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep. 2018 Dec 1;22(12):78.10.1007/s11916-018-0735-z30291554Search in Google Scholar

7. Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B et al. Male and female sex hormones in primary headaches. The journal of headache and pain. 2018 Dec;19(1):117.10.1186/s10194-018-0922-7675557530497379Search in Google Scholar

8. Dalmau LG, Navarro EG, Cuella EC, Santafe M. Factores dietéticos involucrados en la migraña aguda. Revisión sistemática. Rev Esp Nutr Comunitaria. 2018;24(1).Search in Google Scholar

9. Csépány, É., et al. Current pharmacotherapy in migraine. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesület lapja. 2015, 17.4: 169-176.Search in Google Scholar

10. Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacology & therapeutics. 2006 Oct;112(1):199-212.10.1016/j.pharmthera.2005.04.01016797716Search in Google Scholar

11. Tajti J, Szok D, Csáti A, Vécsei L. Prophylactic drug treatment of migraine in children and adolescents: an update. Curr Pain Headache Rep. 2016 Jan;20(1):1.10.1007/s11916-015-0536-626695061Search in Google Scholar

12. Bohm PE, Stancampiano FF, Rozen TD. Migraine Headache: Updates and Future Developments. Mayo Clinic Proceedings 2018 Nov;93(11):1648-165310.1016/j.mayocp.2018.09.00630392545Search in Google Scholar

13. Schwedt TJ. Preventive Therapy of Migraine. Continuum (Minneap Minn). 2018 Aug;24(4):1052-65.10.1212/CON.000000000000063530074549Search in Google Scholar

14. Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol. 2019 Mar 4;15(3):189-98.10.1080/17425255.2019.157874930714429Search in Google Scholar

15. Munksgaard SB, Madsen SK, Wienecke T. Treatment of Medication Overuse Headache–a review. Acta Neurol Scand. 2019 May;139(5):405-414.10.1111/ane.1307430710346Search in Google Scholar

16. Waldman SD. Atlas of Common Pain Syndromes E-Book. Elsevier Health Sciences; 2018.Search in Google Scholar

17. Cargnin S, Viana M, Sances G, Cantello R, Tassorelli C, Terrazzino S. Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. Int J Clin Pharmacol Ther. 2019 Feb;59(2):288-94.10.1002/jcph.132030256423Search in Google Scholar

18. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989 Sep;39(9):1239-.10.1212/WNL.39.9.12392475821Search in Google Scholar

19. Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation, and development. Expert opinion on pharmacotherapy. 2017 Mar;18(4):387-97.10.1080/14656566.2017.128872128129702Search in Google Scholar

20. Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Therapeutic drug monitoring. 2008 Feb;30(1):5.10.1097/FTD.0b013e318162c89b364455018223456Search in Google Scholar

21. Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache: The Journal of Head and Face Pain. 2008 May;48(5):685-7.10.1111/j.1526-4610.2008.01097.x18471110Search in Google Scholar

22. Chadha N, Silakari O. Indoles: As Multitarget Directed Ligands in Medicinal Chemistry. In: Silakari O editor. Key Heterocycle Cores for Designing Multitargeting Molecules Silakari. Amsterdam: Elsevier. 2018. p. 285-321.10.1016/B978-0-08-102083-8.00008-XSearch in Google Scholar

23. ***European Pharmacopoeia 9th Edition, European Department for the Quality of Medicines within the Council of Europe, Strasbourg, 2016.Search in Google Scholar

24. ***The United States Pharmacopoeia 37-National Formulary 32, Rockville, 2014Search in Google Scholar

25. https://www.ema.europa.eu/en (Megtekintés dátuma: 2019.05.13.)Search in Google Scholar

26. https://www.anm.ro/nomenclator/medicamente (Megtekintés dátuma: 2019.05.13.)Search in Google Scholar

27. DOS 3 320 521 (Glaxo; appl. 6.7.1983; GB-prior. 7.6.1982).Search in Google Scholar

28. Velickova N. Drugs like risks factors for oral-facial clefts. Macedonian Pharmaceutical Bulletin, 2011(57):147-8.Search in Google Scholar

29. Komsta L, Waksmundzka-Hajnos M, Sherma J, editors. Thin layer chromatography in drug analysis. Taylor & Francis; 2014, 344.10.1201/b15637Search in Google Scholar

30. El-Bagary RI, Mohammed NG, Nasr HA. Two chromatographic methods for the determination of some antimigraine drugs. Anal Chem Insights. 2012 jan;7:13-21.10.4137/ACI.S8864336232822654488Search in Google Scholar

31. Srinivasu MK, Rao BM, Sridhar G, Kumar PR, Chandrasekhar KB, Islam A. A validated chiral LC method for the determination of zolmitriptan and its potential impurities, J Pharm Biomed Anal. 2005 Mar;37(3):453-60.10.1016/j.jpba.2004.10.02115740903Search in Google Scholar

32. Rezk MR, Michael AM, Lotfy HM, El-Kadi AO, Shehata MA. A rapid and sensitive HPLC assay of some concomitant anti-migraine drugs. J Chromatogr Sci. 2013 Jul;52(7):704-6.10.1093/chromsci/bmt10323845885Search in Google Scholar

33. Rao BM, Srinivasu MK, Sridhar G, Kumar PR, Chandrasekhar KB, Islam A. A stability indicating LC method for zolmitriptan. J pharmaceutl biomed. 2005 Sep;39(3-4):503-9.10.1016/j.jpba.2005.04.01815899567Search in Google Scholar

34. Ahmed S, Atia NN. Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. J pharmaceutl biomed. 2017 Sep;143:241-51.10.1016/j.jpba.2017.05.04728618340Search in Google Scholar

35. Saka C. Review of analytical methods for identification and determination of triptans. Critical Reviews in Analytical Chemistry. 2009 Feb 3;39(1):32-42.10.1080/10408340802569522Search in Google Scholar

36. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995 Mar;2(1):5-21.10.1111/j.1468-1331.1995.tb00087.x24283575Search in Google Scholar

37. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016 May;5:637.10.1186/s40064-016-2211-8487057927330903Search in Google Scholar

38. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. The American Journal of Medicine Supplements. 2005 Mar;118:36-44.10.1016/j.amjmed.2005.01.01815841886Search in Google Scholar

39. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010 Aug;70(12):1505-18.10.2165/11537990-000000000-0000020687618Search in Google Scholar

40. Aurélia U, János T, László V. A migrénes roham kezelése trip-tánokkal. Lege Artis Medicinae. 2004 Mar;14(3):191-7.Search in Google Scholar

41. Mathew NT, Loder EW. Evaluating the triptans. The American Journal of Medicine Supplements. 2005 Mar;118:28-35.10.1016/j.amjmed.2005.01.01715841885Search in Google Scholar

42. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 Mar;2(2):123-32.10.1517/14740338.2.2.12312904112Search in Google Scholar

43. Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.10.1124/dmd.31.7.861Search in Google Scholar

44. Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS drugs. 2012 Sep;26(9):791-811.10.2165/11209380-000000000-00000Search in Google Scholar

45. Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S. Frovatriptan: a review of drug-drug interactions. J Headache Pain. 2002 Apr;42:63-73.10.1046/j.1526-4610.42.s2.4.xSearch in Google Scholar

46. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia. 2004 Jun;24(6):417-24.10.1111/j.1468-2982.2004.00694.xSearch in Google Scholar

47. Meiyanti M. The role of triptans in the management of migraine. Universa Medicina. 2016 Feb;28(1):49-58.10.18051/UnivMed.2009.v28.49-58Search in Google Scholar

48. Ostroff JL, Ostroff ML. An Overview of Generic Triptans for Migraine. US Pharm. 2017;42(6):14-8.Search in Google Scholar

49. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 Mar;2(2):123-32.10.1517/14740338.2.2.123Search in Google Scholar

50. Mathew NT, Loder EW. Evaluating the triptans. The American Journal of Medicine Supplements. 2005 Mar;118:28-35.10.1016/j.amjmed.2005.01.017Search in Google Scholar

51. Buzzi MG. Triptan efficacy in migraine attacks: from appropriate diagnosis to metabolic profiles and pharmacogenomics. Drug Dev Res. 2007 Sep;68(6):335-40.10.1002/ddr.20197Search in Google Scholar

52. Roberto G, Piccinni C, D’Alessandro R, Poluzzi E. Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia. 2014 Jan;34(1):5-13.10.1177/0333102413499649Search in Google Scholar

53. Tepper SJ. Safety and rational use of the triptans. Medical Clinics of North America. 2001 Jul;85(4):959-70.10.1016/S0025-7125(05)70353-9Search in Google Scholar

54. https://www.fda.gov/ (Megtekintés dátuma: 2019.05.13.)Search in Google Scholar

55. Chaplin S, MacGregor A. Triptans: properties and use in the treatment of acute migraine. Prescriber. 2012 Sep 5;23(17):45-8.10.1002/psb.953Search in Google Scholar

56. Tajti J, Majláth Z, Szok D, Csáti A, Vécsei L. Drug safety in acute migraine treatment. Expert Opin Drug Saf. 2015 Jun;14(6):891-909.10.1517/14740338.2015.102632525773005Search in Google Scholar

57. Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert opinion on pharmacotherapy. 2013 Aug;14(12):1659-67.10.1517/14656566.2013.81020923786565Search in Google Scholar

58. Lionetto L, Casolla B, Mastropietri F, D’Alonzo L, Negro A, Simmaco M et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1043-50.10.1517/17425255.2012.70161822762358Search in Google Scholar

59. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004 Jan;4(1):33-41.10.1586/14737175.4.1.3315853613Search in Google Scholar

60. Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust. 2008 Sep;189(5):283-8.10.5694/j.1326-5377.2008.tb02028.x18759728Search in Google Scholar

61. Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000 Nov;20(Suppl 1):2-9.10.1046/j.1468-2982.2000.020s1002.x11078003Search in Google Scholar

62. Cady RK, Farmer K. Managing migraine by patient profile: role of frovatriptan. Patient Prefer Adherence. 2016 Apr;10:5019510.10.2147/PPA.S85795482919227103792Search in Google Scholar

63. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol. 2011 Nov 1;7(11):1449-58.10.1517/17425255.2011.62226521929465Search in Google Scholar

64. Negro A, Lionetto L, D’Alonzo L, Casolla B, Marsibilio F, Vignaroli G, et al. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2013 May;9(5):637-44.10.1517/17425255.2013.78301223570251Search in Google Scholar

65. Gras J, Llenas J, Jansat JM, Jáuregui J, Cabarrocas X, Palacios JM. Almotriptan, a new anti-migraine agent: A review. CNS drug reviews. 2002 Sep;8(3):217-34.10.1111/j.1527-3458.2002.tb00226.x674168712353056Search in Google Scholar

66. Sandrini G, Perrotta A, Nappi G. Eletriptan: a review and new perspectives. Expert Rev Neurother. 2006 Oct 1;6(10):1413-21.10.1586/14737175.6.10.141317078782Search in Google Scholar

67. Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A et al. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Therapeutic advances in neurological disorders. 2016 Sep;9(5):414-23.10.1177/1756285616650619499478027582896Search in Google Scholar

68. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021926s000TOC.cfm (Megtekintés dátuma: 2019.05.13.)Search in Google Scholar